Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

Melanoma harboring BRAF mutations frequently develop resistance to BRAF inhibitors, limiting the impact of treatment. Here, we establish a mechanism of resistance and subsequently identified a suitable drug combination to overcome the resistance. Single treatment of BRAF mutant melanoma cell lines w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747351/
https://www.ncbi.nlm.nih.gov/pubmed/26497853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747351/
https://www.ncbi.nlm.nih.gov/pubmed/26497853

Ejemplares similares